NCT00472758 - A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

March 31, 2008

Conditions

Chronic Plaque Psoriasis

Interventions

BIOLOGICAL

MEDI 545

IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg

OTHER

Placebo

IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg

Trial Locations (3)

Innovaderm Research, Laval, Inc., Laval-Quebec

Innovaderm Research, Inc., Montreal

Probity Medical Research, Waterloo- Ontario